[HTML][HTML] Temperature sensitive liposome based cancer nanomedicine enables tumour lymph node immune microenvironment remodelling
S Fu, L Chang, S Liu, T Gao, X Sang, Z Zhang… - Nature …, 2023 - nature.com
Targeting tumour immunosuppressive microenvironment is a crucial strategy in
immunotherapy. However, the critical role of the tumour lymph node (LN) immune …
immunotherapy. However, the critical role of the tumour lymph node (LN) immune …
Dual mitigation of immunosuppression combined with photothermal inhibition for highly effective primary tumor and metastases therapy
J Huang, L Zhang, W Zhou, J Wang, R Zhang, Z Wang… - Biomaterials, 2021 - Elsevier
T-cell based immune response can attack cancer cells formidably when certain immune
checkpoint (eg, PD-1/PD-L1) is blocked. Unfortunately, PD-1/PD-L1 blockade only provoke …
checkpoint (eg, PD-1/PD-L1) is blocked. Unfortunately, PD-1/PD-L1 blockade only provoke …
Engineering nanoparticles to locally activate T cells in the tumor microenvironment
D Wang, T Wang, H Yu, B Feng, L Zhou, F Zhou… - Science …, 2019 - science.org
Immunological tolerance of tumors is characterized by insufficient infiltration of cytotoxic T
lymphocytes (CTLs) and immunosuppressive microenvironment of tumor. Tumor resistance …
lymphocytes (CTLs) and immunosuppressive microenvironment of tumor. Tumor resistance …
[HTML][HTML] Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy
Current cancer immunotherapy has limited response rates in a large variety of solid tumors
partly due to the low immunogenicity of the tumor cells and the immunosuppressive tumor …
partly due to the low immunogenicity of the tumor cells and the immunosuppressive tumor …
Lyophilizable and multifaceted toll-like receptor 7/8 agonist-loaded nanoemulsion for the reprogramming of tumor microenvironments and enhanced cancer …
The low therapeutic efficacy of current cancer immunotherapy is related to nonimmunogenic
and immunosuppressive tumor microenvironments (TMEs). To overcome these limitations …
and immunosuppressive tumor microenvironments (TMEs). To overcome these limitations …
[HTML][HTML] In-situ cryo-immune engineering of tumor microenvironment with cold-responsive nanotechnology for cancer immunotherapy
Cancer immunotherapy that deploys the host's immune system to recognize and attack
tumors, is a promising strategy for cancer treatment. However, its efficacy is greatly restricted …
tumors, is a promising strategy for cancer treatment. However, its efficacy is greatly restricted …
Modulation of tumor microenvironment using a TLR-7/8 agonist-loaded nanoparticle system that exerts low-temperature hyperthermia and immunotherapy for in situ …
PM Chen, WY Pan, CY Wu, CY Yeh, C Korupalli… - Biomaterials, 2020 - Elsevier
Most cancer vaccines under development are associated with defined tumor antigens rather
than with all antigens of whole tumor cells, limiting the anti-tumor immune responses that …
than with all antigens of whole tumor cells, limiting the anti-tumor immune responses that …
Combining PD-L1 inhibitors with immunogenic cell death triggered by chemo-photothermal therapy via a thermosensitive liposome system to stimulate tumor-specific …
J Yu, X He, Z Wang, Y Wang, S Liu, X Li, Y Huang - Nanoscale, 2021 - pubs.rsc.org
Immune checkpoint blockade (ICB) therapy in combination with immunogenic death (ICD)
triggered by photothermal therapy (PTT) and oxaliplatin (OXA) treatment was expected to …
triggered by photothermal therapy (PTT) and oxaliplatin (OXA) treatment was expected to …
Multifunctional lipid bilayer nanocarriers for cancer immunotherapy in heterogeneous tumor microenvironments, combining immunogenic cell death stimuli with …
In addition to the contribution of cancer cells, the solid tumor microenvironment (TME) has a
critical role in determining tumor expansion, antitumor immunity, and the response to …
critical role in determining tumor expansion, antitumor immunity, and the response to …
[HTML][HTML] Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy
Y Xu, J Xiong, X Sun, H Gao - Acta Pharmaceutica Sinica B, 2022 - Elsevier
Cancer immunotherapy has significantly flourished and revolutionized the limited
conventional tumor therapies, on account of its good safety and long-term memory ability …
conventional tumor therapies, on account of its good safety and long-term memory ability …